JP2016106149A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016106149A5 JP2016106149A5 JP2016051146A JP2016051146A JP2016106149A5 JP 2016106149 A5 JP2016106149 A5 JP 2016106149A5 JP 2016051146 A JP2016051146 A JP 2016051146A JP 2016051146 A JP2016051146 A JP 2016051146A JP 2016106149 A5 JP2016106149 A5 JP 2016106149A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- acceptable salt
- hepatitis
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 4
- 208000005176 Hepatitis C Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41481810P | 2010-11-17 | 2010-11-17 | |
| US61/414,818 | 2010-11-17 | ||
| US201161504924P | 2011-07-06 | 2011-07-06 | |
| US61/504,924 | 2011-07-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539970A Division JP5905020B2 (ja) | 2010-11-17 | 2011-11-16 | 抗ウイルス化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017240524A Division JP2018039851A (ja) | 2010-11-17 | 2017-12-15 | 抗ウイルス化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016106149A JP2016106149A (ja) | 2016-06-16 |
| JP2016106149A5 true JP2016106149A5 (OSRAM) | 2016-10-20 |
Family
ID=45099196
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539970A Active JP5905020B2 (ja) | 2010-11-17 | 2011-11-16 | 抗ウイルス化合物 |
| JP2016051146A Pending JP2016106149A (ja) | 2010-11-17 | 2016-03-15 | 抗ウイルス化合物 |
| JP2017240524A Withdrawn JP2018039851A (ja) | 2010-11-17 | 2017-12-15 | 抗ウイルス化合物 |
| JP2019206819A Withdrawn JP2020037584A (ja) | 2010-11-17 | 2019-11-15 | 抗ウイルス化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013539970A Active JP5905020B2 (ja) | 2010-11-17 | 2011-11-16 | 抗ウイルス化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017240524A Withdrawn JP2018039851A (ja) | 2010-11-17 | 2017-12-15 | 抗ウイルス化合物 |
| JP2019206819A Withdrawn JP2020037584A (ja) | 2010-11-17 | 2019-11-15 | 抗ウイルス化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9156823B2 (OSRAM) |
| EP (3) | EP3284741A1 (OSRAM) |
| JP (4) | JP5905020B2 (OSRAM) |
| KR (5) | KR20180026563A (OSRAM) |
| AR (1) | AR083711A1 (OSRAM) |
| AU (3) | AU2011328980B2 (OSRAM) |
| CA (3) | CA2817840A1 (OSRAM) |
| ES (1) | ES2634095T3 (OSRAM) |
| HK (1) | HK1250162A1 (OSRAM) |
| IL (1) | IL226346A (OSRAM) |
| NZ (2) | NZ726475A (OSRAM) |
| PL (1) | PL2640719T3 (OSRAM) |
| PT (1) | PT2640719T (OSRAM) |
| SG (2) | SG190785A1 (OSRAM) |
| SI (1) | SI2640719T1 (OSRAM) |
| TW (3) | TWI548629B (OSRAM) |
| UY (1) | UY33735A (OSRAM) |
| WO (1) | WO2012068234A2 (OSRAM) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4032897B1 (en) | 2003-05-30 | 2025-01-29 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
| MX363732B (es) | 2009-05-13 | 2019-04-01 | Gilead Pharmasset Llc Star | Compuestos antivirales. |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| DK2368890T3 (da) | 2009-06-11 | 2013-07-22 | Abbvie Bahamas Ltd | Hepatitis C-virusinhibitorer |
| US20130296311A1 (en) * | 2010-05-28 | 2013-11-07 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| TWI548629B (zh) | 2010-11-17 | 2016-09-11 | 吉李德製藥公司 | 抗病毒化合物 |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| CA2840242C (en) | 2011-09-16 | 2019-03-26 | Gilead Sciences, Inc. | Methods for treating hcv |
| PL2635588T3 (pl) * | 2011-11-16 | 2015-10-30 | Gilead Pharmasset Llc | Skondensowane imidazoliloimidazole jako związki antywirusowe |
| AU2015252077A1 (en) * | 2011-11-16 | 2015-11-19 | Gilead Pharmasset Llc | Antiviral compounds |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2013217224B2 (en) | 2012-02-10 | 2017-04-06 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US9079887B2 (en) * | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US9233974B2 (en) * | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| KR20200060782A (ko) | 2013-01-31 | 2020-06-01 | 길리애드 파마셋 엘엘씨 | 두 항바이러스 화합물의 병용 제형물 |
| US10032995B2 (en) | 2013-02-07 | 2018-07-24 | Kyulux, Inc. | Compound having diazatriphenylene ring structure, and organic electroluminescent device |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US20140343008A1 (en) * | 2013-05-16 | 2014-11-20 | Gilead Pharmasset Llc | Hepatitis c treatment |
| CN104211677B (zh) * | 2013-05-30 | 2018-02-23 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
| CN104211565A (zh) * | 2013-05-31 | 2014-12-17 | 浙江九洲药业股份有限公司 | 一种抗丙型肝炎药物中间体的制备方法 |
| EP3015456A4 (en) | 2013-06-26 | 2016-11-16 | Zhejiang Jiuzhou Pharm Co Ltd | PROCESS FOR PREPARING PYRROLIDIN-2-CARBOXYLIC ACID DERIVATIVES |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| WO2015009744A1 (en) | 2013-07-17 | 2015-01-22 | Bristol-Myers Squibb Company | Combinations comprising biphenyl derivatives for use in the treatment of hcv |
| WO2015030854A1 (en) * | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| EP3650014B1 (en) * | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| CN104418784B (zh) * | 2013-09-04 | 2019-02-19 | 浙江九洲药业股份有限公司 | 一种抗病毒药物中间体的拆分方法 |
| WO2015089810A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Fused tetracyclic heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| CA2935089C (en) * | 2013-12-31 | 2018-11-27 | Nanjing Sanhome Pharmaceutical Co., Ltd. | 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene hepatitis c virus inhibitor and application thereof |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| WO2015184644A1 (zh) * | 2014-06-06 | 2015-12-10 | 爱博新药研发(上海)有限公司 | 抑制丙肝病毒的化合物、药物组合物及其应用 |
| TWI679203B (zh) | 2014-06-11 | 2019-12-11 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| CA2951147A1 (en) * | 2014-06-12 | 2015-12-17 | Gilead Sciences, Inc. | Antiviral compounds |
| SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| CN104592124B (zh) * | 2015-01-04 | 2018-01-02 | 华南理工大学 | 一种萘[1,2]并咪唑双极性共轭化合物及制备与应用 |
| TWI703141B (zh) * | 2015-03-12 | 2020-09-01 | 大陸商廣東東陽光藥業有限公司 | 作為丙型肝炎抑制劑的化合物及其在藥物中的應用 |
| WO2016202232A1 (zh) * | 2015-06-19 | 2016-12-22 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法 |
| CN106256819B (zh) * | 2015-06-19 | 2019-07-09 | 重庆博腾制药科技股份有限公司 | 一种(4S)-N-Boc-4-甲氧基甲基-L-脯氨酸胺盐的合成方法 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR101919194B1 (ko) * | 2015-09-15 | 2018-11-15 | 주식회사 엘지화학 | 헤테로고리 화합물 및 이를 포함하는 유기 발광 소자 |
| WO2017181383A1 (en) * | 2016-04-21 | 2017-10-26 | Merck Sharp & Dohme Corp. | Hepatitis c virus inhibitors |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP3463469B1 (en) | 2016-05-27 | 2023-12-13 | Gilead Sciences, Inc. | Combination of ledipasvir and sofosbuvir for use in the treatment of hepatitis b virus infections in humans |
| CN106432197B (zh) * | 2016-09-07 | 2019-12-10 | 上海众强药业有限公司 | 一种雷迪帕韦中间体单对甲苯磺酸盐、其晶型及其制备方法 |
| CN107573355B (zh) * | 2016-11-30 | 2020-03-17 | 上海博志研新药物技术有限公司 | 维帕他韦、其中间体及制备方法 |
| WO2018138050A1 (de) | 2017-01-26 | 2018-08-02 | Bayer Aktiengesellschaft | Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| PL3706762T3 (pl) | 2017-12-07 | 2025-02-10 | Emory University | N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe |
| JP7062792B2 (ja) | 2018-02-13 | 2022-05-06 | ギリアード サイエンシーズ， インコーポレイテッド | Ｐｄ－１／ｐｄ－ｌ１阻害剤 |
| EP3781556B1 (en) | 2018-04-19 | 2025-06-18 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| WO2019222146A1 (en) | 2018-05-15 | 2019-11-21 | University Of Louisville Research Foundation, Inc. | Urolithin a and derivatives thereof for use in therapy |
| CN118221646A (zh) | 2018-07-13 | 2024-06-21 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| KR102635333B1 (ko) | 2018-10-24 | 2024-02-15 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| KR102316919B1 (ko) | 2019-11-28 | 2021-10-22 | 서울시립대학교 산학협력단 | 피지컬 컴퓨팅 소프트웨어를 이용한 코딩 교육 교재 및 이를 활용한 코딩 교육 방법 |
| CN111018870B (zh) * | 2019-11-29 | 2021-07-23 | 南京正济医药研究有限公司 | 一种维帕他韦中间体的制备方法 |
| CA3166630A1 (en) | 2020-01-03 | 2021-07-08 | Berg Llc | Polycyclic amides as ube2k modulators for treating cancer |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| CN112877379B (zh) * | 2021-01-18 | 2023-09-01 | 华南理工大学 | 一种化学酶法合成n-[(3r,6r)-6-甲基哌啶-3-基]氨基甲酸叔丁酯的方法 |
| CA3219397A1 (en) * | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Tetracyclic compounds for the treatment of zika virus infection |
| CA3220903A1 (en) | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Pentacyclic derivatives as zika virus inhibitors |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816570A (en) | 1982-11-30 | 1989-03-28 | The Board Of Regents Of The University Of Texas System | Biologically reversible phosphate and phosphonate protective groups |
| US4968788A (en) | 1986-04-04 | 1990-11-06 | Board Of Regents, The University Of Texas System | Biologically reversible phosphate and phosphonate protective gruops |
| DE69115694T2 (de) | 1990-06-13 | 1996-10-17 | Arnold Newton Mass. Glazier | Phosphorylierte prodrugs |
| DE10399025I2 (de) | 1990-09-14 | 2007-11-08 | Acad Of Science Czech Republic | Wirkstoffvorläufer von Phosphonaten |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US5858389A (en) | 1996-08-28 | 1999-01-12 | Shaker H. Elsherbini | Squalene is an antiviral compound for treating hepatitis C virus carriers |
| CA2448737C (en) | 2001-07-20 | 2010-06-01 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| KR101164070B1 (ko) | 2003-05-09 | 2012-07-12 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃ형 간염 바이러스 ｎｓ5ｂ 폴리머라제 억제제 결합 포켓 |
| US7157492B2 (en) | 2004-02-26 | 2007-01-02 | Wyeth | Dibenzo chromene derivatives and their use as ERβ selective ligands |
| EP2316839B1 (en) | 2004-07-16 | 2014-03-12 | Gilead Sciences, Inc. | Antiviral heterocyclic compounds having phosphonate groups |
| WO2006089231A2 (en) * | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues |
| US8891379B2 (en) | 2006-06-02 | 2014-11-18 | Riverbed Technology, Inc. | Traffic flow inference based on link loads and gravity measures |
| US8329159B2 (en) | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7759495B2 (en) | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20090291138A1 (en) | 2006-12-07 | 2009-11-26 | Daiichi Sankyo Company, Limited | Film-coated preparation having improved stability |
| US7741347B2 (en) | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| NZ587323A (en) * | 2008-02-12 | 2012-02-24 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| JP5312486B2 (ja) * | 2008-02-13 | 2013-10-09 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎ウイルス阻害剤 |
| US8147818B2 (en) * | 2008-02-13 | 2012-04-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7704992B2 (en) | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| WO2010062821A1 (en) * | 2008-11-28 | 2010-06-03 | Glaxosmithkline Llc | Anti-viral compounds, compositions, and methods of use |
| WO2010065681A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| CA2753313A1 (en) * | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| KR20130130875A (ko) * | 2009-02-27 | 2013-12-02 | 이난타 파마슈티칼스, 인코포레이티드 | Ｃ형 간염 바이러스 억제제 |
| CA2756255A1 (en) | 2009-03-27 | 2010-09-30 | Presidio Pharmaceuticals, Inc. | Substituted bicyclic hcv inhibitors |
| KR20110131312A (ko) | 2009-03-27 | 2011-12-06 | 프레시디오 파마슈티칼스, 인코포레이티드 | 융합된 고리 ｃ형 간염 억제제 |
| WO2010132538A1 (en) | 2009-05-12 | 2010-11-18 | Schering Corporation | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| MX363732B (es) * | 2009-05-13 | 2019-04-01 | Gilead Pharmasset Llc Star | Compuestos antivirales. |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| US8138215B2 (en) * | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PE20120993A1 (es) | 2009-09-04 | 2012-08-22 | Janssen Pharmaceuticals Inc | Derivados bifenilicos como antivirales |
| US9156818B2 (en) * | 2009-09-11 | 2015-10-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| CA2782024A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| US8377980B2 (en) * | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011075607A1 (en) | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| WO2011087740A1 (en) * | 2009-12-22 | 2011-07-21 | Schering Corporation | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| CN102918049A (zh) | 2010-03-09 | 2013-02-06 | 默沙东公司 | 稠合三环甲硅烷基化合物及其用于治疗病毒性疾病的方法 |
| US9125904B1 (en) * | 2010-05-11 | 2015-09-08 | Achillion Pharmaceuticals, Inc. | Biphenyl imidazoles and related compounds useful for treating HCV infections |
| WO2011146401A1 (en) * | 2010-05-17 | 2011-11-24 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| BR112013004520A2 (pt) * | 2010-08-26 | 2016-06-07 | Univ Emory | inibidores potentes e seletivos do virus da hepatite c |
| WO2012048421A1 (en) * | 2010-10-14 | 2012-04-19 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor compounds |
| TWI548629B (zh) | 2010-11-17 | 2016-09-11 | 吉李德製藥公司 | 抗病毒化合物 |
| WO2012087976A2 (en) * | 2010-12-21 | 2012-06-28 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| PL2635588T3 (pl) | 2011-11-16 | 2015-10-30 | Gilead Pharmasset Llc | Skondensowane imidazoliloimidazole jako związki antywirusowe |
| US9079887B2 (en) | 2012-05-16 | 2015-07-14 | Gilead Sciences, Inc. | Antiviral compounds |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| US9233974B2 (en) | 2012-12-21 | 2016-01-12 | Gilead Sciences, Inc. | Antiviral compounds |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| WO2015030854A1 (en) | 2013-08-27 | 2015-03-05 | Gilead Pharmasset Llc | Solid dispersion formulation of an antiviral compound |
| TWI679203B (zh) | 2014-06-11 | 2019-12-11 | 美商基利法瑪席特有限責任公司 | 製備抗病毒化合物之方法 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| JP2016051146A (ja) | 2014-09-02 | 2016-04-11 | ウシオ電機株式会社 | 光検出装置 |
-
2011
- 2011-11-16 TW TW100141839A patent/TWI548629B/zh active
- 2011-11-16 KR KR1020187005807A patent/KR20180026563A/ko not_active Ceased
- 2011-11-16 CA CA2817840A patent/CA2817840A1/en not_active Abandoned
- 2011-11-16 TW TW106129863A patent/TWI640526B/zh active
- 2011-11-16 KR KR1020197036217A patent/KR20190140486A/ko not_active Ceased
- 2011-11-16 WO PCT/US2011/060966 patent/WO2012068234A2/en not_active Ceased
- 2011-11-16 CA CA3095528A patent/CA3095528C/en active Active
- 2011-11-16 EP EP17169675.0A patent/EP3284741A1/en not_active Withdrawn
- 2011-11-16 US US13/884,578 patent/US9156823B2/en active Active
- 2011-11-16 EP EP11791700.5A patent/EP2640719B1/en active Active
- 2011-11-16 AU AU2011328980A patent/AU2011328980B2/en active Active
- 2011-11-16 TW TW105118984A patent/TWI607011B/zh active
- 2011-11-16 ES ES11791700.5T patent/ES2634095T3/es active Active
- 2011-11-16 SG SG2013036223A patent/SG190785A1/en unknown
- 2011-11-16 NZ NZ726475A patent/NZ726475A/en unknown
- 2011-11-16 EP EP19215845.9A patent/EP3699176A3/en not_active Withdrawn
- 2011-11-16 NZ NZ710567A patent/NZ710567A/en unknown
- 2011-11-16 KR KR1020137015201A patent/KR101835474B1/ko active Active
- 2011-11-16 KR KR1020207034568A patent/KR20200140924A/ko not_active Ceased
- 2011-11-16 AR ARP110104276 patent/AR083711A1/es active IP Right Grant
- 2011-11-16 UY UY33735A patent/UY33735A/es not_active Application Discontinuation
- 2011-11-16 PL PL11791700T patent/PL2640719T3/pl unknown
- 2011-11-16 SG SG10201509456SA patent/SG10201509456SA/en unknown
- 2011-11-16 SI SI201131200A patent/SI2640719T1/sl unknown
- 2011-11-16 PT PT117917005T patent/PT2640719T/pt unknown
- 2011-11-16 KR KR1020197002491A patent/KR20190012271A/ko not_active Ceased
- 2011-11-16 CA CA3102625A patent/CA3102625C/en active Active
- 2011-11-16 JP JP2013539970A patent/JP5905020B2/ja active Active
-
2013
- 2013-05-13 IL IL226346A patent/IL226346A/en active IP Right Grant
-
2015
- 2015-07-30 US US14/814,392 patent/US10344019B2/en active Active
-
2016
- 2016-03-15 JP JP2016051146A patent/JP2016106149A/ja active Pending
-
2017
- 2017-04-13 AU AU2017202461A patent/AU2017202461A1/en not_active Abandoned
- 2017-12-15 JP JP2017240524A patent/JP2018039851A/ja not_active Withdrawn
-
2018
- 2018-07-24 HK HK18109580.7A patent/HK1250162A1/en unknown
-
2019
- 2019-03-20 AU AU2019201939A patent/AU2019201939C1/en active Active
- 2019-05-23 US US16/421,330 patent/US20200123132A1/en not_active Abandoned
- 2019-11-15 JP JP2019206819A patent/JP2020037584A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016106149A5 (OSRAM) | ||
| JP2017186358A5 (OSRAM) | ||
| JP2014507446A5 (OSRAM) | ||
| JP2018024670A5 (OSRAM) | ||
| JP2017105793A5 (OSRAM) | ||
| JP2015078230A5 (OSRAM) | ||
| JP2018048154A5 (OSRAM) | ||
| JP2019524883A5 (OSRAM) | ||
| JP2020097577A5 (OSRAM) | ||
| JP2021502388A5 (OSRAM) | ||
| JP2017533930A5 (OSRAM) | ||
| JP2016522254A5 (OSRAM) | ||
| EA201890654A1 (ru) | Терапевтические композиции для лечения вируса иммунодефицита человека | |
| JP2016539157A5 (OSRAM) | ||
| JP2016510326A5 (OSRAM) | ||
| JP2016540015A5 (OSRAM) | ||
| JP2015516419A5 (OSRAM) | ||
| JP2016523260A5 (OSRAM) | ||
| JP2018501215A5 (OSRAM) | ||
| JP2019529514A5 (OSRAM) | ||
| HRP20191121T1 (hr) | Tretman multiple skleroze | |
| JP2017522300A5 (OSRAM) | ||
| JP2016532632A5 (OSRAM) | ||
| JP2017516835A5 (OSRAM) | ||
| JP2016533368A5 (OSRAM) |